Company Profile

Apogee Biotechnology Corporation (AKA: Apogee Technology)
Profile last edited on: 12/27/19      CAGE: 46D87      UEI: J9Q4KEGSLWY9

Business Identifier: Orally available, small-molecule inhibitors for the treatment of cancer and inflammatory diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1214 Research Boulevard Suite 2014
Hummelstown, PA 17036
   (843) 876-2498
Location: Single
Congr. District: 10
County: Dauphin

Public Profile

Spun out of Penn State College of Medicine's Department of Pharmacology, Apogee Biotechnology Corporation is developing chemical compounds designed to inhibit the activities of sphingosine kinase, an enzyme known to drive cell proliferation and inflammation. Sphingosine kinase is overactive in several diseases such as cancer, diabetic retinopathy, inflammatory bowel disease, arthritis and atherosclerosis.develops compounds for the treatment of cancer. The lead compound developed by Apogee was identified in 2006 - first-in-class non-lipid inhibitor of sphingosine kinase.The firm's primary technology platform, ABC294640, is an oral small molecule that includes inhibitors of sphingosine kinase for the treatment of solid tumors and various chronic inflammatory diseases, as well as in indications of damaging acute inflammation. In 2015, ABC294640 was licensed to RedHill BioPharma. In addition, the company's focus is on technologies to treat solid tumor cancers that have been validated in preclinical animal tumor models including renal cell carcinoma, breast, brain, pancreatic, myeloma and colon cancers.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Charles D Smith -- President and CEO

  Charles E Ducker

  Leo R Fitzpatrick

  Kevin J French

  Silvan Lutkewitte -- Director, Business Development

  Lynn W Maines -- Vice President, Research and Business Affairs

  Christopher H Parsons

  Randy Schrecengost

  Herbert M Stein

  Zuping Xia

  Zhi Zhong

  Yan Zhuang